hVIVO plc (AIM & Euronext: HVO), a fast growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that
hVIVO PLC (AIM:HVO) £2.5m contract for Omicron characterisation study
£2.5m Contract for Omicron characterisation study
hVIVO PLC (AIM:HVO) positioned for success, according to a US investment bank
In its latest investment research note, Stifel highlights hVIVO PLC’s strong position in the global healthcare market, notably in conducting human challenge clinical trials (HCTs) for infectious and respiratory diseases.
hVIVO PLC (AIM & Euronext: HVO) Final results
A record year across all financial and operational metrics On track to deliver future growth targets Initiating annual dividend policy